Lund, Sweden – May 6, 2025 – MedVasc AB, a Swedish medical technology company announces the successful closing of a SEK 10 million financing round earlier this year. The funding supports the company’s final product development phase and preparation for regulatory approval in the United States.
The primary focus of the investment will be to fund the production and testing of the final design of Solutio™, required for FDA clearance. Regulatory submission is planned for the first half of 2026.
“We are very pleased with the continued confidence from our investors,” says Cathrin Johansson, CEO of MedVasc AB. “This investment gives us the opportunity to take decisive steps towards reaching the US market, which is an important milestone in our growth journey.”
Solutio™ is designed to enable safe and precise local anesthesia during minimally invasive vascular procedures (compatible with thermal ablation treatment fibers), offering a new level of control and patient comfort for clinicians treating chronic venous disorders.
The financing round attracted both existing owners and new investors, demonstrating continued strong confidence in MedVasc’s technology and market potential.
In addition, MedVasc will raise an additional round during 2025 for investments in clinical and preclinical activities required for FDA clearance.
For more information, please contact:
Cathrin Johansson, CEO, MedVasc AB
